Literature DB >> 25637532

Hypercholesterolemia abrogates the protective effect of ischemic postconditioning by induction of apoptosis and impairment of activation of reperfusion injury salvage kinase pathway.

Nan Wu1, Xiaowen Zhang2, Pengyu Jia3, Dalin Jia4.   

Abstract

Ischemic postcontioning (IPoC) is an effective method to prevent myocardial ischemia reperfusion injury (MIRI), but its cardioprotection is usually blocked in the presence of hypercholesterolemia (HC) and the potential mechanism is still unknown. In this study, we investigated the roles of reperfusion injury salvage kinase (RISK) and apoptosis-related pathways in the attenuation of cardioprotection of IPoC in the presence of HC. The results showed that IPoC significantly decreased the infarct size and apoptosis, improved the recovery of ischemic myocardium, but these beneficial effects were reversed by high cholesterol diet-induced HC. Moreover, we also found that HC inhibited the phosphorylation of Akt and ERK1/2 which usually activated by IPoC in normal heart, induced excessive apoptosis by down-regulating Bcl-2 and up-regulating Bax, cytochrome c, caspase 9 and caspase 3 when compared with that in normal heart. Taken together, our results demonstrated that the cardioprotection of IPoC was abolished by HC, which was associated with inactivation of RISK signal pathway and dysregulation of downstream apoptosis-related pathway.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; Hypercholesterolemia; Ischemia reperfusion injury; Ischemic postcoditioning; Reperfusion injury salvage kinase

Mesh:

Substances:

Year:  2015        PMID: 25637532     DOI: 10.1016/j.bbrc.2015.01.084

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

Review 1.  Effect of hypercholesterolaemia on myocardial function, ischaemia-reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning.

Authors:  Ioanna Andreadou; Efstathios K Iliodromitis; Antigone Lazou; Anikó Görbe; Zoltán Giricz; Rainer Schulz; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2017-02-08       Impact factor: 8.739

Review 2.  Myocyte membrane and microdomain modifications in diabetes: determinants of ischemic tolerance and cardioprotection.

Authors:  Jake Russell; Eugene F Du Toit; Jason N Peart; Hemal H Patel; John P Headrick
Journal:  Cardiovasc Diabetol       Date:  2017-12-04       Impact factor: 9.951

3.  The Rise of ST-Elevation Myocardial Infarction in Women of Northeast China.

Authors:  Yihe Wang; Gary S Newsome
Journal:  Gerontol Geriatr Med       Date:  2021-02-15

4.  Acute atorvastatin treatment restores the cardioprotective effects of ischemic postconditioning in hyperlipidemic rats.

Authors:  Tao Sun; Hong-Ju Zhang; Chayakrit Krittanawong; Su Wang; Ying Tao; Zhao Li; Qiancheng Yin; Donghua Zhang; Qian Wang; Ji Huang; Jingmei Zhang; Zhizhong Li; Yutong Cheng
Journal:  Oncotarget       Date:  2017-07-14

5.  AT1 Receptor Modulator Attenuates the Hypercholesterolemia-Induced Impairment of the Myocardial Ischemic Post-Conditioning Benefits.

Authors:  Yun-Wei Li; Yan-Ming Li; Yan Hon; Qi-Lin Wan; Rui-Li He; Zhi-Zhong Wang; Cui-Hua Zhao
Journal:  Korean Circ J       Date:  2017-03-13       Impact factor: 3.243

6.  Intra-coronary morphine versus placebo in the treatment of acute ST-segment elevation myocardial infarction: the MIAMI randomized controlled trial.

Authors:  Philippe Le Corvoisier; Romain Gallet; Pierre-François Lesault; Etienne Audureau; Muriel Paul; Julien Ternacle; Saïd Ghostine; Stéphane Champagne; Raphaele Arrouasse; Dalila Bitari; Gauthier Mouillet; Jean-Luc Dubois-Randé; Alain Berdeaux; Bijan Ghaleh; Jean-François Deux; Emmanuel Teiger
Journal:  BMC Cardiovasc Disord       Date:  2018-10-19       Impact factor: 2.298

7.  Lycopene protects against myocardial ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening.

Authors:  Xuying Li; Pengyu Jia; Zijun Huang; Shuang Liu; Jiaxin Miao; Yuxuan Guo; Nan Wu; Dalin Jia
Journal:  Drug Des Devel Ther       Date:  2019-07-11       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.